Saturable binding of finasteride to steroid 5a-reductase as determinant of nonlinear pharmacokinetics

Rie Suzuki, Hiroki Satoh, Hisakazu Ohtani, Satoko Hori, Sawada Yasufumi

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Finasteride, a steroid 5a-reductase (5aR) inhibitor, is used to treat benign prostatic hyperplasia and androgenetic alopecia. We aimed to develop a pharmacokinetic/pharmacodynamic model to explain its nonlinear pharmacokinetics and describe the serum concentration profile of dihydrotestosterone (DHT) after finasteride administration. We developed a pharmacokinetic model incorporating a compartment that represents the binding of finasteride to 5aR. We fitted this model to the time-concentration profiles of finasteride after repeated administration of finasteride 0.2 and 1 mg/day. We constructed a pharmacodynamic model considering the inhibition of 5aR type I and type II (5aR1 and 5aR2). This model was fitted to the time profiles of serum DHT. The developed pharmacokinetic model well described nonlinear increase in AUC after repeated administration of finasteride. The association and dissociation rate constants were estimated to be 0.0293/nmol/hr and 0.0185/hr, respectively. Pharmacodynamic model analysis suggested that the 5aR1 inhibition is dose-dependent in the dose range from 0.2 to 100 mg, while the 5aR2 inhibition is almost saturated in the same dose range. Finasteride's saturable binding to 5aR2 is the likely cause of its nonlinear pharmacokinetics. The developed pharmacokinetic/pharmacodynamic model should allow prediction of plasma concentration profiles of finasteride and DHT.

Original languageEnglish
Pages (from-to)208-213
Number of pages6
JournalDrug Metabolism and Pharmacokinetics
Volume25
Issue number2
DOIs
Publication statusPublished - 2010
Externally publishedYes

Fingerprint

Finasteride
Oxidoreductases
Pharmacokinetics
Steroids
Dihydrotestosterone
Alopecia
Prostatic Hyperplasia
Serum
Area Under Curve

Keywords

  • 5α-reductase
  • Dihydrotestosterone
  • Finasteride
  • Nonlinear pharmacokinetics
  • Pharmacokinetic/pharmacodynamic modeling

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology
  • Pharmaceutical Science

Cite this

Saturable binding of finasteride to steroid 5a-reductase as determinant of nonlinear pharmacokinetics. / Suzuki, Rie; Satoh, Hiroki; Ohtani, Hisakazu; Hori, Satoko; Yasufumi, Sawada.

In: Drug Metabolism and Pharmacokinetics, Vol. 25, No. 2, 2010, p. 208-213.

Research output: Contribution to journalArticle

Suzuki, Rie ; Satoh, Hiroki ; Ohtani, Hisakazu ; Hori, Satoko ; Yasufumi, Sawada. / Saturable binding of finasteride to steroid 5a-reductase as determinant of nonlinear pharmacokinetics. In: Drug Metabolism and Pharmacokinetics. 2010 ; Vol. 25, No. 2. pp. 208-213.
@article{31d3265430314d59bdca44d7ef48d975,
title = "Saturable binding of finasteride to steroid 5a-reductase as determinant of nonlinear pharmacokinetics",
abstract = "Finasteride, a steroid 5a-reductase (5aR) inhibitor, is used to treat benign prostatic hyperplasia and androgenetic alopecia. We aimed to develop a pharmacokinetic/pharmacodynamic model to explain its nonlinear pharmacokinetics and describe the serum concentration profile of dihydrotestosterone (DHT) after finasteride administration. We developed a pharmacokinetic model incorporating a compartment that represents the binding of finasteride to 5aR. We fitted this model to the time-concentration profiles of finasteride after repeated administration of finasteride 0.2 and 1 mg/day. We constructed a pharmacodynamic model considering the inhibition of 5aR type I and type II (5aR1 and 5aR2). This model was fitted to the time profiles of serum DHT. The developed pharmacokinetic model well described nonlinear increase in AUC after repeated administration of finasteride. The association and dissociation rate constants were estimated to be 0.0293/nmol/hr and 0.0185/hr, respectively. Pharmacodynamic model analysis suggested that the 5aR1 inhibition is dose-dependent in the dose range from 0.2 to 100 mg, while the 5aR2 inhibition is almost saturated in the same dose range. Finasteride's saturable binding to 5aR2 is the likely cause of its nonlinear pharmacokinetics. The developed pharmacokinetic/pharmacodynamic model should allow prediction of plasma concentration profiles of finasteride and DHT.",
keywords = "5α-reductase, Dihydrotestosterone, Finasteride, Nonlinear pharmacokinetics, Pharmacokinetic/pharmacodynamic modeling",
author = "Rie Suzuki and Hiroki Satoh and Hisakazu Ohtani and Satoko Hori and Sawada Yasufumi",
year = "2010",
doi = "10.2133/dmpk.25.208",
language = "English",
volume = "25",
pages = "208--213",
journal = "Drug Metabolism and Pharmacokinetics",
issn = "1347-4367",
publisher = "Japanese Society for the Study of Xenobiotics",
number = "2",

}

TY - JOUR

T1 - Saturable binding of finasteride to steroid 5a-reductase as determinant of nonlinear pharmacokinetics

AU - Suzuki, Rie

AU - Satoh, Hiroki

AU - Ohtani, Hisakazu

AU - Hori, Satoko

AU - Yasufumi, Sawada

PY - 2010

Y1 - 2010

N2 - Finasteride, a steroid 5a-reductase (5aR) inhibitor, is used to treat benign prostatic hyperplasia and androgenetic alopecia. We aimed to develop a pharmacokinetic/pharmacodynamic model to explain its nonlinear pharmacokinetics and describe the serum concentration profile of dihydrotestosterone (DHT) after finasteride administration. We developed a pharmacokinetic model incorporating a compartment that represents the binding of finasteride to 5aR. We fitted this model to the time-concentration profiles of finasteride after repeated administration of finasteride 0.2 and 1 mg/day. We constructed a pharmacodynamic model considering the inhibition of 5aR type I and type II (5aR1 and 5aR2). This model was fitted to the time profiles of serum DHT. The developed pharmacokinetic model well described nonlinear increase in AUC after repeated administration of finasteride. The association and dissociation rate constants were estimated to be 0.0293/nmol/hr and 0.0185/hr, respectively. Pharmacodynamic model analysis suggested that the 5aR1 inhibition is dose-dependent in the dose range from 0.2 to 100 mg, while the 5aR2 inhibition is almost saturated in the same dose range. Finasteride's saturable binding to 5aR2 is the likely cause of its nonlinear pharmacokinetics. The developed pharmacokinetic/pharmacodynamic model should allow prediction of plasma concentration profiles of finasteride and DHT.

AB - Finasteride, a steroid 5a-reductase (5aR) inhibitor, is used to treat benign prostatic hyperplasia and androgenetic alopecia. We aimed to develop a pharmacokinetic/pharmacodynamic model to explain its nonlinear pharmacokinetics and describe the serum concentration profile of dihydrotestosterone (DHT) after finasteride administration. We developed a pharmacokinetic model incorporating a compartment that represents the binding of finasteride to 5aR. We fitted this model to the time-concentration profiles of finasteride after repeated administration of finasteride 0.2 and 1 mg/day. We constructed a pharmacodynamic model considering the inhibition of 5aR type I and type II (5aR1 and 5aR2). This model was fitted to the time profiles of serum DHT. The developed pharmacokinetic model well described nonlinear increase in AUC after repeated administration of finasteride. The association and dissociation rate constants were estimated to be 0.0293/nmol/hr and 0.0185/hr, respectively. Pharmacodynamic model analysis suggested that the 5aR1 inhibition is dose-dependent in the dose range from 0.2 to 100 mg, while the 5aR2 inhibition is almost saturated in the same dose range. Finasteride's saturable binding to 5aR2 is the likely cause of its nonlinear pharmacokinetics. The developed pharmacokinetic/pharmacodynamic model should allow prediction of plasma concentration profiles of finasteride and DHT.

KW - 5α-reductase

KW - Dihydrotestosterone

KW - Finasteride

KW - Nonlinear pharmacokinetics

KW - Pharmacokinetic/pharmacodynamic modeling

UR - http://www.scopus.com/inward/record.url?scp=77952633692&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77952633692&partnerID=8YFLogxK

U2 - 10.2133/dmpk.25.208

DO - 10.2133/dmpk.25.208

M3 - Article

VL - 25

SP - 208

EP - 213

JO - Drug Metabolism and Pharmacokinetics

JF - Drug Metabolism and Pharmacokinetics

SN - 1347-4367

IS - 2

ER -